Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticlePediatric Rheumatology

Schizophrenia Genetics and Neuropsychiatric Features in Childhood-onset Systemic Lupus Erythematosus

Ana C. Ulloa, Fangming Liao, Raffaella L. Carlomagno, Talia Diaz, Daniela Dominguez, Deborah M. Levy, Lawrence Ng, Andrea M. Knight and Linda T. Hiraki
The Journal of Rheumatology February 2022, 49 (2) 192-196; DOI: https://doi.org/10.3899/jrheum.210363
Ana C. Ulloa
1A.C. Ulloa, MPH, Genetics & Genome Biology, Research Institute, The Hospital for Sick Children;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ana C. Ulloa
Fangming Liao
2F. Liao, MSc, R.L. Carlomagno, MD, T. Diaz, MD, D. Dominguez, MD, MSc, L. Ng, BSc, A.M. Knight, MD, MSCE, Division of Rheumatology, The Hospital for Sick Children;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raffaella L. Carlomagno
2F. Liao, MSc, R.L. Carlomagno, MD, T. Diaz, MD, D. Dominguez, MD, MSc, L. Ng, BSc, A.M. Knight, MD, MSCE, Division of Rheumatology, The Hospital for Sick Children;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Talia Diaz
2F. Liao, MSc, R.L. Carlomagno, MD, T. Diaz, MD, D. Dominguez, MD, MSc, L. Ng, BSc, A.M. Knight, MD, MSCE, Division of Rheumatology, The Hospital for Sick Children;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Dominguez
2F. Liao, MSc, R.L. Carlomagno, MD, T. Diaz, MD, D. Dominguez, MD, MSc, L. Ng, BSc, A.M. Knight, MD, MSCE, Division of Rheumatology, The Hospital for Sick Children;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniela Dominguez
Deborah M. Levy
3D.M. Levy, MD, MS, Division of Rheumatology, The Hospital for Sick Children, and Department of Pediatrics, The University of Toronto;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Deborah M. Levy
Lawrence Ng
2F. Liao, MSc, R.L. Carlomagno, MD, T. Diaz, MD, D. Dominguez, MD, MSc, L. Ng, BSc, A.M. Knight, MD, MSCE, Division of Rheumatology, The Hospital for Sick Children;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea M. Knight
2F. Liao, MSc, R.L. Carlomagno, MD, T. Diaz, MD, D. Dominguez, MD, MSc, L. Ng, BSc, A.M. Knight, MD, MSCE, Division of Rheumatology, The Hospital for Sick Children;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda T. Hiraki
4L.T. Hiraki, MD, FRCPC, ScD, Genetics & Genome Biology, Research Institute, and Division of Rheumatology, The Hospital for Sick Children, and Department of Pediatrics, The University of Toronto, Toronto, Ontario, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Linda T. Hiraki
  • For correspondence: linda.hiraki@sickkids.ca
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective We examined the association between schizophrenia genetic susceptibility loci and neuropsychiatric systemic lupus erythematosus (NPSLE) features in childhood-onset SLE (cSLE) participants.

Methods Study participants from the Lupus Clinic at the Hospital for Sick Children, Toronto, met ≥ 4 of the American College of Rheumatology and/or SLE International Collaborating Clinics SLE classification criteria and were genotyped using the Illumina Multi-Ethnic Global Array or the Global Screening Array. Ungenotyped single-nucleotide polymorphisms (SNPs) were imputed, and ancestry was genetically inferred. We calculated 2 additive schizophrenia-weighted polygenic risk scores (PRS) using (1) genome-wide significant SNPs (P < 5 × 10–8), and (2) an expanded list of SNPs with significance at P < 0.05. We defined 2 outcomes compared to absence of NPSLE features: (1) any NPSLE feature, and (2) subtypes of NPSLE features (psychosis and nonpsychosis NPSLE). We completed logistic and multinomial regressions, first adjusted for inferred ancestry only and then added for variables significantly associated with NPSLE in our cohort (P < 0.05).

Results We included 513 participants with cSLE. Median age at diagnosis was 13.8 years (IQR 11.2–15.6), 83% were female, and 31% were of European ancestry. An increasing schizophrenia genome-wide association PRS was not associated with NPSLE (OR 1.04, 95% CI 0.87–1.26, P = 0.62), nor with the NPSLE subtypes, psychosis (OR 0.97, 95% CI 0.73–1.29, P = 0.84) and other nonpsychosis NPSLE (OR 1.08, 95% CI 0.88–1.34, P = 0.45), in ancestry-adjusted models. Results were similar for the model including covariates (ancestry, malar rash, oral/nasal ulcers, arthritis, lymphopenia, Coombs-positive hemolytic anemia, lupus anticoagulant, and anticardiolipin antibodies) and for the expanded PRS estimates.

Conclusion We did not observe an association between known risk loci for schizophrenia and NPSLE in a multiethnic cSLE cohort. This work warrants further validation.

Key Indexing Terms:
  • childhood
  • genetics
  • neuropsychiatric lupus
  • rheumatology
  • schizophrenia
  • systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with varying clinical presentations that can affect virtually any organ system. Genetics plays an important role in SLE susceptibility, with heritability estimates of up to 66% and over 100 susceptibility single-nucleotide polymorphisms (SNPs).1 Genetics also contributes to the risk of developing certain SLE clinical features, including neuropsychiatric SLE (NPSLE).2

NPSLE features are heterogeneous; can involve the peripheral or central nervous system; and include psychosis, other nonpsychosis features (e.g., acute confusional state, cerebrovascular disease, seizure), and less SLE-specific symptoms such as headaches and mood or anxiety disorders.3 The prevalence of NPSLE in childhood-onset SLE (cSLE) is estimated to be up to 95% depending on the NPSLE case definition used.4 While there is no gold standard for NPSLE diagnosis, the American College of Rheumatology (ACR) published case definitions for NPSLE in 1999.3

Morbidity and mortality vary across cSLE cohorts. Some studies of cSLE participants show that when compared to cSLE without NPSLE, NPSLE is associated with disease-associated damage. Damage most frequently included cataracts as well as the musculoskeletal, neuropsychiatric, and renal systems.5,6,7

Schizophrenia is a severe, chronic psychiatric disorder with heterogeneous manifestations including hallucinations, delusions, cognitive impairment, and disorganized or abnormal motor behavior. It is strongly influenced by genetics, with heritability estimates of nearly 80% and over 100 risk loci identified by genome-wide association studies (GWAS).8 These prior GWAS demonstrate that schizophrenia is a polygenic disease, with many risk loci also linked with other disorders such as autism spectrum disorder, bipolar disorder, and major depressive disorder.8,9

Large-scale studies have also demonstrated significant comorbid and genetic associations between schizophrenia and several autoimmune diseases, including SLE.10,11 Schizophrenia GWAS have identified risk loci in the major histocompatibility complex (MHC), which encodes numerous immune-related genes involved in antigen presentation and inflammation. Other schizophrenia genetic risk loci associated with immunity outside of the MHC region have also been found, such as those encoding for CD19 and CD20 B lymphocytes. These suggest that inflammation and immune dysregulation may be important disease mechanisms for schizophrenia.8 No study to date has examined the relationship between genetic risk loci for schizophrenia and NPSLE risk. The purpose of this study was to examine the association between polygenic risk scores (PRS) for schizophrenia and both NPSLE and specific NPSLE features, in a multiethnic cohort of participants with cSLE. This approach enabled testing for pleiotropy (1 gene influencing ≥ 2 unrelated phenotypes) with schizophrenia and NPSLE, as well a link between schizophrenia genetic risk and NPSLE in children and adolescents with SLE.

METHODS

Study population. The study cohort included participants diagnosed with and followed for cSLE between 1983 and 2018 in the Lupus Clinic at the Hospital for Sick Children (SickKids), a tertiary care center in Toronto, Canada. Participants met ≥ 4 of the 1997 ACR revised criteria for SLE diagnosis and/or the 2012 SLE International Collaborating Clinics (SLICC) criteria.12,13

Genotyping and imputation. Participants were genotyped using the Illumina Multi-Ethnic Global Array (MEGA) or the Global Screening Array (GSA; Illumina Inc.).14,15 Genotyping was conducted following protocols specified by The Centre for Applied Genomics at SickKids (see quality control [QC] measures in the Supplementary Methods, available with the online version of this article). SNPs not genotyped were imputed using the Sanger Imputation Server and the Haplotype Reference Consortium (HRC) and 1000 Genomes Project (1KGP) phase 3 as references.16 For participants with inferred European ancestry, HLA allele dosages were imputed using SNP2HLA and Type 1 Diabetes Genetics Consortium as a reference.17,18

PRS calculations. We selected SNPs for inclusion in schizophrenia PRS based on the most comprehensive schizophrenia GWAS conducted to date by the Schizophrenia Working Group of the Psychiatric Genomics Consortium (SWG-PGC).8 Utilizing the SWG-PGC PRS calculation for schizophrenia, and QC procedures as guiding principles (Supplementary Methods, available with the online version of this article), we computed 2 PRS using (1) genome-wide significant SNPs (P < 5 × 10–8), and (2) an expanded set of SNPs showing significance at a threshold of P < 0.05. After excluding SNPs through QC procedures, the GWAS PRS included 76/128 SWG-PGC SNPs and the extended PRS included 15,305/24,850 SNPs.

We used these SNPs to calculate additive, allelic schizophrenia PRS for each participant by identifying the risk alleles, weighting the allele dosages by the log odds ratios (log(ORs)) from the SWG-PGC study, and summing up the values to derive the PRS.8

Outcome measures. Demographic, clinical, and laboratory features for all participants were extracted from the SickKids Lupus Database, with details supplemented by medical records when required. NPSLE features were defined using the 1999 ACR list of case definitions for NPSLE.3 Features were independently validated by 2 pediatric rheumatologists (RLC and TD). In the case of discrepancies, additional pediatric rheumatologists (LTH, AMK, DML) acted as tiebreakers. We defined 2 outcomes compared to absence of NPSLE features: (1) any NPSLE feature, and (2) subtypes of NPSLE features (psychosis and nonpsychosis NPSLE features).

Covariates. Ancestry was inferred using 1KGP and the HRC as referents (Supplementary Methods, available with the online version of this article). The software tool ADMIXTURE was used to estimate relative proportions of ancestral groups within discordant subjects.19 Participants with single ancestral proportions ≥ 80% were classified into 1 of 5 ancestral groups: African, Amerindian, East Asian, European, or South Asian. Participants displaying ancestral proportions < 80% were classified as “Admixed.”

We also calculated SLE non-HLA PRS in all participants and SLE HLA PRS in ancestral European participants, by weighting allele dosages using log(ORs) obtained from the largest multiethnic SLE GWAS study conducted to date.1

Statistical analyses. We calculated counts and proportions for categorical variables and medians and IQRs for continuous variables. We compared the characteristics of those with and without NPSLE using chi-square statistics for categorical values and Wilcoxon rank-sum test for continuous variables.

We tested the association between PRS for schizophrenia and NPSLE using logistic and multinomial logistic regression. We ran univariate models and multivariable models adjusted for (1) inferred ancestry categories (European, Admixed, African, East Asian, South Asian), and (2) variables significantly associated with NPSLE in our cohort (P < 0.05). We conducted the multivariable-adjusted analysis to account for NPSLE risk and to increase power to detect genetic effects in our cohort. We calculated ORs, 95% CIs, and P values.

We also tested the association between each of the following and NPSLE: each individual genome-wide significant SNP (using a Bonferroni-corrected P value threshold of 6.58 × 10–4 [0.05/76]) and 2 SNPs located in the MHC region (rs115329265 and rs114541829) that were significant at a threshold of P < 0.05 in the SWG-PGC study but not included in their PRS calculations. To test the association between known SLE susceptibility loci and NPSLE, we regressed SLE non-HLA PRS and NPSLE, and SLE HLA PRS and NPSLE among European participants.

We completed 3 sensitivity analyses for less NPSLE-specific features of headache, anxiety, and/or mood disorders. First, we censored these participants from analyses. Second, we included them as controls. Last, we included them in their own subcategory of NPSLE features. All analyses were conducted in R version 3.6.3.20 This project was approved by the SickKids Institutional Research Ethics Board (REB #1000058324).

RESULTS

Our study cohort consisted of 513 participants, of which 424 (83%) were female. The median age at SLE diagnosis was 13.8 (IQR 11.2–15.6) years, and the median follow-up duration was 4.6 (IQR 2.8–7.5) years. Genetically inferred ancestry indicated that most participants were European (n = 157, 31%) or East Asian (n = 143, 28%). Four-hundred seventy-one participants were genotyped on the MEGA array, and 42 were genotyped on the GSA array. A total of 201 had any NPSLE feature (39%; Table 1). Inferred ancestry categories, malar rash, oral or nasal ulcers, arthritis, lymphopenia, Coombs-positive hemolytic anemia, and lupus anticoagulant and/or anticardiolipin antibodies were all significantly associated with NPSLE in our cohort (P < 0.05; Table 1). Of the 201 participants with NPSLE, subtype classification resulted in 60 (30%) participants with psychosis as a feature and 141 (70%) with nonpsychosis features (Table 2).

View this table:
  • View inline
  • View popup
Table 1.

Demographic characteristics and clinical and laboratory features of cohort (n = 513).

View this table:
  • View inline
  • View popup
Table 2.

Characteristics of NPSLE features among study cases by category (n = 201).

An increase in the GWAS PRS for schizophrenia was not significantly associated with increased odds of having any NPSLE feature vs no features (OR 1.04, 95% CI 0.87–1.26, P = 0.62) in ancestry-adjusted models (Table 3). Similarly, an increase in the GWAS PRS for schizophrenia was not significantly associated with increased odds of having psychosis (OR 0.97, 95% CI 0.73–1.29, P = 0.84) or other nonpsychosis NPSLE features (OR 1.08, 95% CI 0.88–1.34, P = 0.45) compared to no NPSLE. Results did not differ significantly in the univariate or full multivariable-adjusted models (Table 3), nor for the expanded schizophrenia PRS, which remained nonsignificant (Supplementary Table 1, available with the online version of this article).

View this table:
  • View inline
  • View popup
Table 3.

Association between NPSLE, NPSLE subtypes, and schizophrenia GWAS PRS.a

Analyses of individual schizophrenia GWAS SNPs with NPSLE risk in ancestry-adjusted models indicated no significant associations with NPSLE (Supplementary Table 2, available with the online version of this article). Additional analyses of 2 schizophrenia risk SNPs in the MHC region that were excluded from the PRS calculations demonstrated a marginally significant association with NPSLE for rs115329265 (allele G, OR 0.69, 95% CI 0.48–0.97, P = 0.04) and no significant association for rs114541829 (allele G, OR 1.00, 95% CI 0.58–1.73, P > 0.99). We repeated these analyses in the European subset of our cohort (n = 157); however, results were not significant (results not shown).

SLE non-HLA PRS were normally distributed across our study population (P = 0.86). There was no significant association between SLE non-HLA PRS and NPSLE in the total cohort in ancestry-adjusted models (OR 1.21, 95% CI 0.98–1.49, P = 0.07). Results were similar when adjusted for all significant covariates (results not shown).

Of the 157 participants of inferred European ancestry, 76 (48%) had at least 1 NPSLE feature. SLE HLA PRS were not normally distributed across this population (P = 1.04 × 10–5). The distribution of SLE HLA PRS was not significantly different between participants with and without NPSLE (P = 0.64). There was no significant association between SLE HLA PRS and NPSLE (OR 1.17, 95% CI 0.83–1.67, P = 0.37) in the multivariable-adjusted model.

In sensitivity analyses, in (1) censoring participants with headaches, anxiety, and/or mood disorders as their only NPSLE features; (2) including them as controls; or (3) including them in their own subcategory of NPSLE features, we did not find an association between the schizophrenia PRS and NPSLE (results not shown).

DISCUSSION

Our study found no significant association between schizophrenia PRS and overall NPSLE risk, or with specific NPSLE features. We also did not find a significant association between SLE susceptibility loci and NPSLE. In this multiethnic cohort of patients with cSLE, there was no evidence for shared risk between schizophrenia genetic susceptibility loci and NPSLE.

The prevalence of NPSLE in our cohort was consistent with previous reports of NPSLE among cSLE cohorts at 39%, with a high prevalence of headaches (31%), psychosis (12%), and cognitive dysfunction (10%).21 While several studies utilize the 1999 ACR classification criteria to define NPSLE features, there remains a lack of case definition standardization.21 Depending on the manifestations and diagnostic methods, the prevalence of NPSLE reported varies between 22–95% among cSLE cohorts.21 Recognizing these discrepancies, we examined not only overall NPSLE risk, but also NPSLE risk by subtype, given our large cohort and detailed clinical and laboratory data to classify participants into specific subtypes. We defined 2 NPSLE subphenotypes: psychosis and nonpsychosis NPSLE, focusing on the clinical similarity between psychosis in NPSLE and schizophrenia to define subtypes.22 Our sensitivity analyses accounted for potential misclassifications of NPSLE status. With these groupings, we assumed similar relationships between genetic risk and each of the features within each group.

The SWG-PGC study from which we selected SNPs for inclusion in our study represents the largest schizophrenia GWAS conducted to date, including almost 37,000 cases and over 113,000 controls, and over 9 million SNPs tested.8 More recently, GWAS have looked at endophenotypes of schizophrenia, and cross-disorder analyses have looked at the genetic association between schizophrenia and other psychiatric or immune-mediated disorders. However, the SWG-PGC study remains the largest schizophrenia GWAS to date.9,10,11 Some of these studies have found shared genetic risks between SLE and schizophrenia to be mediated primarily by HLA alleles.10,23 We found nonsignificant and marginally significant associations between 2 individual schizophrenia SNPs in the MHC region and overall NPSLE risk in our cohort, suggesting a distinct pathobiology for schizophrenia and NPSLE in cSLE. Our findings warrant further validation.

Our study findings should be considered in light of some limitations. Our cSLE cohort was multiethnic, yet susceptibility loci for schizophrenia were derived from a primarily European GWAS.8 As a result, we may have excluded important non-European susceptibility loci from our PRS. In recent years, there has been an effort to improve representation of ancestrally diverse world populations in genetic studies. However, until the sample sizes for these studies are sufficient, our ability to draw inferences from non-European populations are limited.24,25 A multiethnic schizophrenia meta-GWAS in East Asian and European populations found 53 novel loci.24 Yet, the total number of cases included in this meta-GWAS was still 15,000 less than the SWG-PGC GWAS in Europeans that we used to select SNPs for our PRS. By using the largest GWAS to date, we are including the most robust risk loci for schizophrenia. Due to the highly polymorphic nature of the MHC region, and lack of reliable non-European HLA reference populations, we could only examine HLA alleles in Europeans.10,23 Neuropsychological evaluations were not routinely completed in all patients and neurocognitive function was determined by physician diagnosis. Efforts were made to avoid diagnostic biases by having 2 pediatric rheumatologists independently validate NPSLE features, as described in the methods. Finally, our analyses may have lacked sufficient power to detect significant associations, particularly in the NPSLE subtype analyses and in analyses stratified by ancestry.

Our study has several strengths. To our knowledge, it is the first to examine the association between genetic risk loci for schizophrenia and NPSLE specifically. The detailed clinical, laboratory, and genetic data for this large multiethnic cSLE cohort allowed us to look not only at overall NPSLE risk but also at specific subtypes, and to control for covariates associated with NPSLE in our cohort including ancestry and the presence of arthritis, lymphopenia, and antiphospholipid antibodies.

We did not observe a significant association between genetic risk loci for schizophrenia and NPSLE in a multiethnic cohort of children and adolescents with SLE. To our knowledge, our study is the first of its kind and requires additional validation in adult-onset SLE cohorts and independent childhood-onset SLE cohorts. Our observed lack of association between schizophrenia risk loci and NPSLE does not obviate a role for genetics for NPSLE risk. A genome-wide interrogation of NPSLE-specific manifestations is warranted. Knowledge of the genetics of NPSLE will provide a better understanding of the molecular mechanisms driving this complex disease, ultimately improving therapy and outcomes for people with SLE.

Footnotes

  • LTH is supported by The Arthritis Society Stars Career Award.

  • The authors declare no conflicts of interest relevant to this article.

  • Accepted for publication September 23, 2021.
  • © 2022 by the Journal of Rheumatology

REFERENCES

  1. 1.↵
    1. Langefeld CD,
    2. Ainsworth HC,
    3. Graham DSC, et al
    . Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun 2017;8:16021.
    OpenUrlPubMed
  2. 2.↵
    1. Ho RC,
    2. Ong H,
    3. Thiaghu C,
    4. Lu Y,
    5. Ho CS,
    6. Zhang MW.
    Genetic variants that are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol 2016;43:541–51.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599–608.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Sibbitt WL,
    2. Brandt JR,
    3. Johnson CR, et al
    . The incidence and prevalence of neuropsychiatric syndromes in pediatric onset systemic lupus erythematosus. J Rheumatol 2002;29:1536–42.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Hiraki LT,
    2. Benseler SM,
    3. Tyrrell PN,
    4. Hebert D,
    5. Harvey E,
    6. Silverman ED.
    Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008;152:550–6.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Groot N,
    2. Shaikhani D,
    3. Teng YKO, et al
    . Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 2019;71:290–301.
    OpenUrlPubMed
  7. 7.↵
    1. Lim LSH,
    2. Lefebvre A,
    3. Benseler S,
    4. Silverman ED.
    Longterm outcomes and damage accrual in patients with childhood systemic lupus erythematosus with psychosis and severe cognitive dysfunction. J Rheumatol 2013;40:513–9.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Schizophrenia Working Group of the Psychiatric Genomics Consortium
    . Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511:421–7.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Greenwood TA,
    2. Lazzeroni LC,
    3. Maihofer AX, et al
    . Genome-wide association of endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study. JAMA Psychiatry 2019;76:1274.
    OpenUrl
  10. 10.↵
    1. Pouget JG, Schizophrenia Working Group of the Psychiatric Genomics Consortium,
    2. Han B, et al
    . Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk. Hum Mol Genet 2019;28:3498–513.
    OpenUrlPubMed
  11. 11.↵
    1. Tylee DS,
    2. Sun J,
    3. Hess JL, et al
    . Genetic correlations among psychiatric and immune-related phenotypes based on genome-wide association data. Am J Med Genet B Neuropsychiatr Genet 2018;177:641–57.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Petri M,
    2. Orbai AM,
    3. Alarcón GS, et al
    . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Hochberg MC.
    Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Infinium Expanded Multi-Ethnic Genotyping Array
    . Illumina; 2015 [Internet. Accessed September 27, 2021.]. Available from: https://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/mega-ex-data-sheet-370-2015-004.pdf
  15. 15.↵
    Global Screening Array-24 v3.0 BeadChip Illumina; 2020 [Internet. Accessed September 27, 2021.] Available from: https://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/infinium-global-screening-array-data-sheet-370-2016-016.pdf
  16. 16.↵
    1. Mills RE,
    2. Walter K,
    3. Stewart C, et al; 1000 Genomes Project
    . Mapping copy number variation by population-scale genome sequencing. Nature 2011;470:59–65.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Rich SS,
    2. Akolkar B,
    3. Concannon P, et al
    . Overview of the Type I Diabetes Genetics Consortium. Genes Immun 2009;10 Suppl 1:S1–4.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Jia X,
    2. Han B,
    3. Onengut-Gumuscu S, et al
    . Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 2013;8:e64683.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Alexander DH,
    2. Novembre J,
    3. Lange K.
    Fast model-based estimation of ancestry in unrelated individuals. Genome Res 2009;19:1655–64.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. R Core Team
    (2021). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [Internet. Accessed September 27, 2021.] Available from: https://www.R-project.org
  21. 21.↵
    1. Postal M,
    2. Costallat LTL,
    3. Appenzeller S.
    Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management. CNS Drugs 2011;25:721–36.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Tiosano S,
    2. Farhi A,
    3. Watad A, et al
    . Schizophrenia among patients with systemic lupus erythematosus: population-based cross-sectional study. Epidemiol Psychiatr Sci 2017;26:424–9.
    OpenUrl
  23. 23.↵
    1. Sekar A,
    2. Bialas AR,
    3. de Rivera H, et al
    . Schizophrenia risk from complex variation of complement component 4. Nature 2016;530:177–83.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Lam M,
    2. Chen CY,
    3. Li Z, et al
    . Comparative genetic architectures of schizophrenia in East Asian and European populations. Nat Genet 2019;51:1670–8.
    OpenUrl
  25. 25.↵
    1. Bigdeli TB,
    2. Genovese G,
    3. Georgakopoulos P, et al
    . Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry. Mol Psychiatry 2019;25:2455–67.
    OpenUrl

ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 49, Issue 2
1 Feb 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Schizophrenia Genetics and Neuropsychiatric Features in Childhood-onset Systemic Lupus Erythematosus
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Schizophrenia Genetics and Neuropsychiatric Features in Childhood-onset Systemic Lupus Erythematosus
Ana C. Ulloa, Fangming Liao, Raffaella L. Carlomagno, Talia Diaz, Daniela Dominguez, Deborah M. Levy, Lawrence Ng, Andrea M. Knight, Linda T. Hiraki
The Journal of Rheumatology Feb 2022, 49 (2) 192-196; DOI: 10.3899/jrheum.210363

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Schizophrenia Genetics and Neuropsychiatric Features in Childhood-onset Systemic Lupus Erythematosus
Ana C. Ulloa, Fangming Liao, Raffaella L. Carlomagno, Talia Diaz, Daniela Dominguez, Deborah M. Levy, Lawrence Ng, Andrea M. Knight, Linda T. Hiraki
The Journal of Rheumatology Feb 2022, 49 (2) 192-196; DOI: 10.3899/jrheum.210363
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
    • ONLINE SUPPLEMENT
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
  • eLetters

Keywords

CHILDHOOD
GENETICS
neuropsychiatric lupus
RHEUMATOLOGY
schizophrenia
SYSTEMIC LUPUS ERYTHEMATOSUS

Related Articles

Cited By...

More in this TOC Section

  • Differentially Expressed Inflammation-Regulating MicroRNAs in Oligoarticular Juvenile Idiopathic Arthritis
  • Reliability of the Pediatric Specific Musculoskeletal Ultrasound Scoring Systems for the Elbow, Wrist, and Finger Joints
  • Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Show more Pediatric Rheumatology

Similar Articles

Keywords

  • childhood
  • genetics
  • neuropsychiatric lupus
  • rheumatology
  • schizophrenia
  • systemic lupus erythematosus

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire